Cite

HARVARD Citation

    Xu, J. et al. (2020). A Phase II Trial of Cabozantinib in Hormone Receptor‐Positive Breast Cancer with Bone Metastases. Oncologist. pp. 652-660. [Online]. 
  
Back to record